VER
Vascular & Endovascular Review

Efficacy of SGLT2 Inhibitors in Reducing Hospitalization for Heart Failure in Patients with Type 2 Diabetes: A Meta-Analysis

Ahmad Naser Karzoun[1], Mohammed Obaidat[2], Omar A. Barakat[3], Amash H. A. Alajmi[4], Ramzi Fakhri Eid Alnassraween[5], Baker Alrosan[6], Mohammad Hisham Abdelaziz Aljarbouah[7], Muhnnad Madi Jaghabir[8]

[1]Department of Internal Medicine, USF Morsani College of Medicine - Blake Medical Center, Bradenton, Florida, USA.
akarzoun7@gmail.com , https://orcid.org/0009-0006-5311-5815
[2]Internal Medicine, Adventist Health Bakersfield, Bakersfield, California, USA.
Obaidam@ah.org, https://orcid.org/0009-0001-9199-3241
[3]Department of Medicine, School of Medicine, Yarmouk University, Irbid, Jordan.
Dr.barakatomar@gmail.com, https://orcid.org/0009-0005-0086-4890
[4]Department of Medicine and Surgery, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan.
ahalajmi19@med.just.edu.jo, https://orcid.org/0009-0007-0172-4827
[5]Department of Medicine, Faculty of Medicine, Yarmouk University, Irbid, Jordan.
Nassraween00@gmail.com, https://orcid.org/0009-0005-2027-1689
[6]Department of Medicine, Faculty of Medicine, Yarmouk University, Irbid, Jordan.
Baker.alrosan@gmail.com, https://orcid.org/0009-0001-4128-5992
[7]Intern, Faculty of Medicine, University of Jordan, Amman, Jordan.
Mohammad.aljarbouah@gmail.com, https://orcid.org/0009-0002-3819-515X
[8]Success International Academy, Amman, Jordan.
jmohnnad@gmail.com, https://orcid.org/0009-0005-0916-8496

ABSTRACT

Background: Type 2 diabetes mellitus (T2D) is a consequence of heart failure (HF), a significant issue in the health care environment, as a disease and death cause and an initiator of health care utilization. Hospitalization cost of heart failure (HHF) is an outcome measure for evaluating the effectiveness of treatment. Methodology: The current study aims to perform a balanced evaluation of the efficacy of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the prevention of HHF among T2D patients through aggregating qualitative numbers of randomized controlled trials (RCTs), observational studies, and clinical approaches. From 2015 to 2025, secondary qualitative meta-analysis was conducted based on evidence from PubMed, Scopus, and Google Scholar. Peer-reviewed randomized controlled trials, cohort studies, and periodical reports were included with the additional effect of SGLT2i on heart failure hospitalization (HHF). Findings: Primary extracting themes were medical efficacy, mechanistic explanation, heterogeneity of subdivisions, and the impact of implementation. The CASP agenda was used to test for bias. Thematic synthesis of the controversial trials reaffirms that SGLT2 inhibitors (SGLT2i) reduce hospitalization for heart failure (HHF) in T2D patients. This has been observed in trials such as EMPA-REG, CANVAS, and DECLARE-TIMI 58. The benefits spread beyond those associated with reduced blood glucose levels and comprise proposed mechanisms such as natriuresis, enhanced renal hemodynamics, and positive cardiac remodelling. Benefits across diverse subpopulations of patients, together with those with or without preceding heart failure and those with chronic kidney disease (CKD), were also found. Conclusions: Thus, there is substantial indication that has influenced clinical practice, leading the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) to recommend that SGLT2i be measured as an early agent for patients at high risk. Additional studies are compulsory to determine patient-centred viewpoints and provincial inequalities in medical implementation.

KEYWORDS: Type 2 Diabetes (T2D), Heart Failure (HF), SGLT 2 Inhibitors (SGLT2i), Hospitalization for Heart Failure (HHF), Cardiovascular Outcomes, Renal Outcomes.

How to Cite: Ahmad Naser Karzoun, Mohammed Obaidat, Omar A. Barakat, Amash H. A. Alajmi, Ramzi Fakhri Eid Alnassraween, Baker Alrosan6, Mohammad Hisham Abdelaziz Aljarbouah, Muhnnad Madi Jaghabir, (2025) Efficacy of SGLT2 Inhibitors in Reducing Hospitalization for Heart Failure in Patients with Type 2 Diabetes: A Meta-Analysis, Vascular and Endovascular Review, Vol.8, No.1s, 47-52.

INTRODUCTION

Type 2 diabetes (T2D) and heart failure (HF) have both meaningfully increased in occurrence internationally and partly share cover pathophysiological mechanisms that worsen consequences. Most significantly, T2D is also a well-known precursor for HF (Gulsin, et al., 2019). The correspondence between the conditions greatly increases cardiovascular adverse events. Hospitalization for heart failure (HHF) is a valuable medical endpoint that specifies both the phase of sickness evolution and treatment efficacy; frequent cases are also predictive factors for inferior prognosis, advanced healthcare expenses, and inferior quality of life. SGLT2 inhibitors, originally made for glycaemic control, have gained great evidence with their extra renal and cardiovascular advantages, such as diuresis, blood pressure decreases, and healthier cardiac function-make them outstanding for their advantage in T2D plus HF patients (Zelniker & Braunwald, 2020). Quantitative meta-analyses have observed SGLT2i efficacy in decreasing HHF; however, very little has been done qualitatively across trials to discover explanations, clinical descriptions, and guideline approvals. This research intended to address this gap by directing a qualitative secondary meta-analysis towards a complete understanding of the influence of SGLT2i on HHF amongst patients with T2D.

Figure 1. SGLT2 Ihibitors' Characteristics (Kurczyński et al., 2022)

Research Objectives

This study includes the following research objectives:

- This study employed a secondary meta-analysis of qualitative data to evaluate the impact of SGLT2 inhibitors on HHF in T2D patients.
- To examine SGLT2i in the context of their mechanistic pathways and medical suggestions that contain cardiovascular and renal assistance in addition to glucose-lowering.
- To explore changes in efficacy, adoption, and standard integration of SGLT2i across various patient subdivisions and real-world medical settings.

Research Questions

To discuss the research objectives, this study aims to answer these questions:

1. What do SGLT2 inhibitors do in decreasing the risk and occurrence of HHF in T2 diabetes patients in various clinical trials?
2. What mechanistic pathways contribute toward cardiovascular and renal assistance by SGLT2i therapy beyond glucose lowering?
3. How do results from the trials explain and are useful in medical practice, as well as how they inform the most current updates in strategies?

LITERATURE REVIEW

In this respect, diverse current randomized controlled trials like the EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58 have been reliable in demonstrating that use of SGLT2 inhibitors decreases heart failure hospitalization and cardiovascular mortality, particularly amongst patients with T2 diabetes. Therefore, the observational suggestion has also reverberated these results concerning their applicability to actual life.

The EMPA-REG OUTCOME trial verified empagliflozin in persons with type 2 diabetes and increased cardiovascular risk. Consequences displayed it is decreasing the number of deaths from heart sickness, overall deaths, and hospitalizations for heart failure. This milestone study verified that the diabetes medicines can also protect the heart, altering treatment approaches for patients (Zinman, et al., 2015).

In the CANVAS Database, over 10,000 persons with type 2 diabetes and increased cardiac risk were given canagliflozin or a placebo for about 3.6 years. Canagliflozin decreased the risk of heart attack, stroke, or cardiac death. It also reduced kidney harm. Though it improved the risk of elimination, particularly of toes or metatarsals, diabetes, and cardiovascular illness (Neal, et al., 2017).

In a sample of over 17,000 persons with type 2 diabetes, as well as some with cardiovascular illness risk, dapagliflozin was associated with placebo over 4.2 years. It did not decrease the main opposing cardiovascular events (MACE), but did reduce rates of cardiovascular death or hospitalization for heart failure. Kidney results also enhanced; all-cause death was a little bit lower, but not statistically significant (Wiviott, et al., 2019).

Empa-REG OUTCOME is one such trial proving that it is partly due to the unanticipated cardiovascular effects of SGLT2 inhibitors, possibly unrelated to glucose control, further establishing the multitargeted nature of these drugs. Real-world data gathered from administrative offices and cohort studies also support these findings by establishing the efficacy of SGLT2 inhibitors across heterogeneous populations as well as clinical environments (Sohee Park, et al., 2023).
Though inconsistency among patient subgroups in treatment effect, for example, between preserved versus diminished ejection fraction or between negative renal function, must be investigated further to maximize and tailor favourable policies.

METHODOLOGY

Study Design

Utilizing a secondary qualitative meta-analysis, this study aimed to structure the analysis and comprehension of qualitative findings from previous guided studies to form a general perception of how SGLT2 inhibitors (SGLT2i) reduce hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D). Such a structure guarantees synthesis of research findings, accumulation of a number of themes, patterns, and visions, surpassing that which is available in each single study (Chen, et al., 2024). A literature search was accomplished through the main electronic databases: PubMed, Scopus, and Google Scholar for study articles available in the years 2015 to 2025. The searches used keywords and MeSH terms related to T2D, HF, HHF, and SGLT2i, while actually studying reference lists of appropriate articles to guarantee complete coverage.

Inclusion and Exclusion Criteria

In the study synthesis, peer-reviewed, randomized controlled trials (RCTs), cohort studies, and recommendation reports that definitely looked at the impact of SGLT2i on HHF in patients with T2D were involved. Patient-centered results, clinical clarification, or guideline recommendations were measured because these were important to the qualitative synthesis (Zhao, et al., 2022).On the contrary, animal-based studies and studies that were morally mechanistic/basic science research were not involved to hold the qualitative integrity and significance of the synthesis. By doing this, it was guaranteed that the included studies would also have a medical background and explanatory perceptions (Ali, et al., 2024).

Data Extraction and Analysis

Data extraction comprised recognising important concepts, persistent themes, and clarifications of authors for each study. These were implied into four conceptual classes: medical effectiveness; mechanistic clarifications beyond glucose control; erraticism across patient subclasses; and application or guideline influence (Zhang & Hao, 2025). A thematic synthesis was then conducted, permitting the incorporation of results from transversal studies, thus revealing patterns, convergences, and divergences, and leading to a more nuanced explanation of SGLT2i impacts on HHF. To evaluate the excellence of studies and the danger of partiality, an improved Critical Appraisal Skills Programme (CASP) qualitative checklist was used for the secondary synthesis, guaranteeing that the assumptions drawn were built on first-class, trustworthy evidence.

RESULTS

Selection of Study

Out of the systematic search, a total of 1,245 records were discovered in PubMed, Scopus, and Google Scholar. After the elimination of duplicates, a total of 1,034 records were designated based on title and abstract. At the end, 187 full-text articles were assessed for suitability. After applying inclusion and exclusion criteria, there are key studies in the final qualitative meta-analysis. A PRISMA-compliant flow chart (Figure 2) displays the study's choice procedure and delivers a strong indication of the records found, divided, omitted, and lastly involved in the analysis.

Thematic Analysis

Constant Decrease in HHF Across Trials

Such possibilities were universal in the main cardiovascular consequence trials with important possibilities about HHF reduction with SGLT2s. In EMPA-REG OUTCOME, HHF was reduced by 35%, while CANVAS stated fairly comparable statistics and therefore established its reproducibility. DECLARE-TIMI 58 was added to the picture by displaying these assistances in patients without previous HF. Overall, these studies agreeably specify the influential efficacy of SGLT2i on HHF and complete cardiovascular consequences. An article reviews the outcome from the CANVAS trial, which assessed canagliflozin in type 2 diabetes patients at cardiovascular risk. Canagliflozin meaningfully decreases main cardiovascular measures and hospitalization for heart failure, but amplifies the risk of elimination and fractures. The results emphasize both cardiovascular assistance and protection discussions in medical use (Shah, et al., 2018).



Figure 2. Role of SGLT2 Inhibitors (Pabel et al., 2021)

Mechanistic Descriptions Beyond Glucose Control

Several mechanisms of cardiovascular support by SGLT2i have been revealed through qualitative analyses. Plasma volume loss caused by natriuresis and osmotic diuresis lowers the afterload and preload on the heart. By optimizing renal hemodynamics, preservation of renal function indirectly maintains cardiac function. Conversely, cardiac remodelling, i.e., reduction in fibrosis and left ventricular hypertrophy, was also identified to be a significant factor providing a better platform for the experiential value added beyond glycemic control. EMPA-REG OUTCOME trial's research estimated empagliflozin in heart failure patients, stratified by anticipated conservation against reduced ejection fraction. Findings showed empagliflozin reduced heart failure hospitalization in both groups equally, suggesting an advantage regardless of ejection fraction, validating its use in total heart failure treatment in type 2 diabetes patients. (Savarese, et al., 2021).

Subdivision-Specific Visions

Just as diverse subdivisions of patients were associated with respect to their diverse effects, the patient populations associated were among preserved and decreased ejection fractions, which established dissimilar response patterns, suggesting that personalised therapy might be essential. Some alterations in assistance related to increasingly deteriorating renal function were obvious amongst patients, but the all-encompassing consensus was that renal function must be followed and therapy adjusted, therefore. These findings set the vision for optimized SGLT2i treatment with revised strategies. The research noted empagliflozin's renal effect in patients with heart failure and

preserved or reduced ejection fraction. Support included less diminishment of renal function and fewer opposing renal effects. Effects were consistent across EF groups, targeting renal one-to-one therapy and enabling personalized SGLT2 inhibitor treatment to maximize outcomes in diverse heart failure populations (Fuster, 2021).

Medical Implementation and Recommendation Effect

The most current ADA and EASD guideline recommendations support using SGLT2 inhibitors in preliminary treatment for patients at high risk for cardiovascular disease due to diabetes, particularly with recognized heart failure or chronic kidney disease. This validates the addition of trials into practice, displaying the extent of research translation into the definitive treatment protocol. Real-world studies also established that there are numerous barriers to application, with physicians' diverse consciousness, local differences in practice, and patient-associated factors being amongst them (Yi, et al., 2023).

Characteristics of Included Studies

Table 1 was essentially a summary of the characteristics of the involved studies: author, year, population of study, kinds of study, and qualitative main results. Then, large randomized controlled trials such as EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58 were involved in this observational cohort study, as well as recommendation reports. Sample sizes extended from 500 to more than 17,000 applicants with a variety of ages, genders, baseline cardiovascular risk, and renal function status. Such variety made it conceivable for a complete valuation of SGLT2i impacts across numerous subdivisions.

Table 1: Summary of the Review

Study	Year	Population	Study Type	Key Findings
EMPA-REG OUTCOME	2015	T2D with high CV risk	RCT	Decreased HHF, enhanced CV results, and mechanistic perceptions beyond glucose control
CANVAS	2017	T2D with CV risk factors	RCT	Constant HHF reduction, diuretic, and renal hemodynamic impacts were observed.
EMPEROR Program	2021	HF with preserved/reduced EF	RCT	Renal outcomes were enhanced, with reduced kidney deterioration, and a constant advantage across EF groups.
Real-World Cohorts	2018-2022	Diverse T2D populations	observational	Established efficacy in routine practice, diverse implementation based on standard awareness

Conceptual Framework

The association among SGLT2 inhibitors, their fundamental actions (natriuresis, renal hemodynamics, and cardiac remodeling), and medical results (reduced HHF, enhanced CV, and renal health) was visually hypothesized into a guide for incorporation. This framework has created the evidence, mechanistic, and patient results into the translational medical influence, which will assist as a reference for future research applications.



Figure 3. Outcomes of SGLT2 Inhibitors (Jaiswal et al., 2023).

DISCUSSION

Interpretation of Findings and Mechanistic Visions

From these results, it appears reliable that sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been effective in decreasing hospitalization for heart failure (HHF) in type 2 diabetes patients. Across the main cardiovascular consequence trials, together with EMPA-REG OUTCOME, CANVAS, and DECLARE-TIMI 58, narratives constantly recommend that decreases in the risk of HHF highlight the reproducible result in diverse patient populations. Beyond glycemic control, the benefits of SGLT2i have been verified by numerous studies, spread to validate renal and cardiovascular compensations. The mechanisms may include natriuresis and osmotic diuresis that act through declining plasma volume and cardiac preload, as well as through positive changes in renal hemodynamics that might benefit preserve renal function and eventually positive cardiac remodeling with reduced left ventricular hypertrophy and fibrosis (Verma & McMurray, 2018). These frequent actual mechanisms may explain the observed medical assistance and complex SGLT2i as intermediaries of glucose declining and cardio-renal security.

Evaluation with Previous Studies, Strengths, and Limitations

Meta-analyses for measurable outcomes reflect that there is a possibility of risk reduction for HHF without mentioning the ubiquitous absence of clinical description or mechanistic insight, and even on certain occasions will an emphasis on inclusion of strategies will be noted. This qualitative synthesis pushes articles, thus combining definitions from trials with patient-based results and real-world evidence. In addition, subcategory analysis identified a discrepancy in response between patients whose cases were maintained in the dimension of having lower ejection fractions and opposing renal functions, indicative of individualization in care. Its power is found in the majority analysis capture complexities since it entails mechanistic, medical, and guideline ideas into an understandable synthesis. Both RCTs and real-life cohort studies are addressed in this research, making the study appropriate for recurrent practice relating to trial settings and decision-making (Anker, et al., 2021). The study limitations are there; however, the second use of qualitative evidence would necessarily create possible publication and journalism biases. Numerical pooling is impossible; therefore, quantification of result sizes is needed. The heterogeneity across studies for heart failure or HHF descriptions, and the exclusion of gray and non-English literature, can also reduce generalizability.

Medical Recommendations and Forthcoming Directions

The synergy has actually broader implications for the practice of medicine. Efficacy of SGLT2i in minimizing HHF is proof of the European Association for the Study of Diabetes (EASD) and the American Diabetes Association (ADA) suggestion of utilization of these medications in patients who are at greater risk of T2DM, such as heart failure or chronic kidney disease (Anson, et al., 2023). Each patient's profile or characteristics need to be considered by the clinician when adjusting therapy: HF phenotype, baseline renal function, and comorbidities. Personalization is required because significant heterogeneity of patient response has been noted. Also, the synthesis identifies areas for future research of possible geographic or demographic variability in SGLT2 inhibitor treatment, evidence mapping to patient-level outcomes, and mechanism studies connecting renal and cardiac effects to clinical outcomes.

This not only gives a general background to inform decision-making but also underpins SGLT2i as an anchor treatment in T2D with associated heart failure by providing both a mechanistic context and a structure for advice in terms of efficacy.

Limitations and Future Research

These factors, mainly with conflicting results, must be taken together with the inherent restrictions of a secondary meta-analysis. First, there seems to be a slight danger that because the current so-called study is purely qualitative and so secondary, the authors would have to rely on how the other studies were designed, described, and reported. Such second-hand valuations run the risk of publication-bias and reporting-bias; studies with either positive or clinically relevant results are the ones that get published and often are included in synthesis analyses; so some opinions, subtleties, or findings opposing others may be underrated, thus compromising the strength of the deductions made (Bartoš, et al., 2024). The other consequence is that the more stringent the requirement for statistical pooling and quantitative meta-analysis, the more that cross-study effect size estimation will be stifled, making any clear conjecture with respect to differences in the efficacy of SGLT2 inhibitors across populations or care settings rather unlikely. Different designs will produce different definitions of heart failure or hospitalization for heart failure in the patient population being compared, thereby undermining the external validity of the findings. In addition, the determinants of eligibility can have limited eligibility to English language, peer-reviewed literature, and thereby exclude relevant prospective data by ruling out non-English studies or literature, which otherwise would still be strongly relevant considerations providing information on other healthcare sites or patient populations (Mheissen, et al., 2024).

Future research should employ mixed designs of quantitative trial data and qualitative patient interviews or focus groups. Such a design would ensure a rigorous and comfortable patient-centred understanding of patients' experience, decision, and perceived gain or disadvantage of SGLT2 inhibition (Palinkas, et al., 2015). Furthermore, real-world archive studies with different populations and medical environments need to confirm and extrapolate trial outcomes and also shed light on generalizability, patterns of adherence, and long-term effects. Finally, research into regional differences in take-up and implementation approaches could further develop best practice so that the advantage of SGLT2 inhibitors is most optimally converted into everyday healthcare provision. To this end, further research may further promote evidence and practice of SGLT2 inhibitor therapy of type 2 diabetes with heart failure (Kosiborod, et al., 2017).

CONCLUSION

This research would indeed affirm the way this technique guarantees that sodium-glucose cotransporter-2 inhibitors (SGLT2i) are protective of hospitalization for heart failure (HHF) in type 2 diabetes (T2D) individuals. Subgroup analyses would show that there is a much more complex treatment plan since there are differences in the response to therapy based on heart failure phenotypes, renal status, and baseline cardiovascular risk. This combination is supported by ADA and EASD guidelines, according to which, in high-risk patients, SGLT2i must be the first-line medication. This practice is now being confirmed by clinical trials or real-life evidence data. It is in line with the vision of SGLT2i to be integrated into standard care programs, within proposals for improving the indicators of patient outcomes and demands of the health system. Nevertheless, additional research needs to examine patient attitudes, local-level patterns of use, and usage patterns to enhance therapy and to ascertain that SGLT2i provides benefits across various clinical scenarios.

REFERENCES

1. Ali, M. U. et al., 2024. The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis. Cardiovasc Diabetol, 23(1), p. 72.
2. Anker, S. D. et al., 2021. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 385(16), pp. 1451-1461.
3. Anson, M. et al., 2023. SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study. Diabetologia, 66(1), pp. 1869–

1881,.
4. Bartoš, F. et al., 2024. Footprint of publication selection bias on meta-analyses in medicine, environmental sciences, psychology, and economics. Research Synthesis Methods,, 15(3), p. 500–511.
5. Chen, J. et al., 2024. Effects of SGLT2 inhibitors on cardiac function and health status in chronic heart failure: a systematic review and meta-analysis. Cardiovascular Diabetology, 23(2), pp. 1-10.
6. Fuster, V., 2021. Technology and the Pandemic: A Tool We Must Wield to Maintain Our Humanity. JACC Journals, 77(8), pp. 1-10.
7. Gulsin, G. S., Athithan, L. & McCann, G. P., 2019. Diabetic cardiomyopathy: prevalence, determinants and potential treatments. Therapeutic Advances in Endocrinology and Metabolism, 1(1), pp. 1-10.
8. Jaiswal, A., Jaiswal, V., Ang, S. P., Hanif, M., Vadhera, A., Agrawal, V., & Biswas, M. (2023). SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials. Medicine, 102(39), e34693.
9. Kosiborod, M. et al., 2017. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotranspo. aha journals, 136(3), pp. 1-10.
10. Kurczyński, D., Hudzik, B., Jagosz, M., Zabierowski, J., Nowak, J., Tomasik, A., ... & Gąsior, M. (2022). Sodium-glucose cotransporter-2 inhibitors-from the treatment of diabetes to therapy of chronic heart failure. Journal of Cardiovascular Development and Disease, 9(7), 225.
11. Mheissen, S., Spineli, L. M., Daraqel, B. & Alsafadi, A. S., 2024. Language bias in orthodontic systematic reviews: A meta-epidemiological study. PLOS One, 19(4), pp. 1-10.
12. Neal, B. et al., 2017. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes (CANVAS Program).. New England Journal of Medicine, 377(7), pp. 644-657.
13. Pabel, S., Hamdani, N., Singh, J., & Sossalla, S. (2021). Potential mechanisms of SGLT2 inhibitors for the treatment of heart failure with preserved ejection fraction. Frontiers in Physiology, 12, 752370
14. Palinkas, L. A. et al., 2015. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Administration and Policy in Mental Health and Mental Health Services Research, 42(1), pp. 553-544.
15. Savarese, G. et al., 2021. Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. Journal of Cardiac Failure, 27(8), pp. 888-895.
16. Shah, S. R. et al., 2018. Canagliflozin and Cardiovascular disease- results of the CANVAS trial. J Community Hosp Intern Med Perspect, 8(5), p. 267–268..
17. Sohee Park, P. et al., 2023. Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study. Cardiovascular Diabetology, 1(1), pp. 1-10.
18. Verma, S. & McMurray, J. J. V., 2018. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia, 61(1), pp. 2108–2117,.
19. Wiviott, S. D. et al., 2019. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med, 380(4), pp. 347-357.
20. Yi, T. W. et al., 2023. Identifying Barriers and Facilitators for Increasing Uptake of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors in British Columbia, Canada, using the Consolidated Framework for Implementation Research. Can J Kidney Health Dis, 1(1), pp. 1-10.
21. Zelniker, T. A. & Braunwald, E., 2020. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review. JACC Journals, 75(4), pp. 1-10.
22. Zhang, Y. & Hao, Z. L. A. Y., 2025. Comparative efficacy of GLP-1 RAs/SGLT-2 inhibitors in reducing cardiovascular events in type 2 diabetes according to baseline use of metformin: a systematic review and meta-analysis of randomized controlled trials. European Journal of Medical Research, 30(13), pp. 1-10.
23. Zhao, Z. et al., 2022. SGLT2 Inhibitors in Diabetic Patients With Cardiovascular Disease or at High Cardiovascular Risk: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Front. Cardiovasc. Med, 9(1), pp. 1-10.
24. Zinman, B. et al., 2015. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes (EMPA-REG OUTCOME). New England Journal of Medicine, 373(22), pp. 2117-2128.